Arrowhead Pharma (ARWR) Stock Price, Quote & News

Company Profile

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, t...

Industry: Biotechnology

Sector: Healthcare

Phone: 626 304 3400

Fax: 626 304 3401

Website: arrowheadpharma.com

Address:

177 East Colorado Boulevard, Suite 700, Pasadena, United States

skeezbag Jul. 9 at 6:40 PM

$ARWR weekly visit to the babysitter to ask for permission

1 · Reply

aliliimr Jul. 9 at 9:36 AM

$ARWR AstraZeneca shares slide after Ionis-partnered drug fails key heart disease trial Do we see impact of this on Arwr? i dont know the technicalities and the similarity between ions and our platform hence asking.

3 · Reply

CDMO Jul. 9 at 7:47 AM

$ARWR IONS having a hard time

0 · Reply

Quantumup Jul. 8 at 3:49 PM

BofA reiterated $BEAM Buy-$47 and said - Limited impact from Prime arbitration loss, '302 still leader in next-gen AATD $PRME GRFS TAK - $ARWR SNY NVO KRRO Here's what BofA went on to say: https://x.com/Quantumup1/status/2074883323986321615?s=20

0 · Reply

BillionerOfKing Jul. 7 at 10:43 PM

$ARWR Current Stock Price: $86.95 Contracts to trade: $87.5 ARWR Jul 17 2026 Call Entry: $2.50 Exit: $4.21 ROI: 69% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

skeezbag Jul. 7 at 7:55 PM

$ARWR now ask yourself why the fake analyst is dropping coverage He has fcs/shtg? He/him is pregnant? M+a table finally flipped?

2 · Reply

johnnygogogo Jul. 7 at 7:40 PM

$ARWR peace out brotha, your fake coverage was always the fakest. @skeezbag

0 · Reply

Jschwarma Jul. 7 at 6:37 PM

$ARWR Leerink dropping coverage, so long Mani!!

2 · Reply

magross24 Jul. 7 at 4:37 PM

$ARWR they are trying so hard!

0 · Reply

magross24 Jul. 7 at 3:40 PM

$ARWR XBI is a freight train…it’s going to be harder to suppress ARWR share price…

0 · Reply

Arrowhead Pharmaceuticals Transcript: Investor update

Jun 29, 2026, 11:30 AM EDT - 10 days ago

Arrowhead Pharmaceuticals Slides: Investor update

2026-06-22T16:35:08.000Z - 17 days ago

Arrowhead receives MAA in the EU for REDEMPLO

Jun 22, 2026, 12:33 PM EDT - 17 days ago

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Jun 18, 2026, 7:30 AM EDT - 21 days ago

Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars

Jun 10, 2026, 9:00 AM EDT - 4 weeks ago

Arrowhead Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 3, 2026, 8:10 AM EDT - 5 weeks ago

Arrowhead Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

Jun 2, 2026, 7:30 AM EDT - 5 weeks ago

Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events

2026-05-27T11:20:49.000Z - 6 weeks ago

Arrowhead presents interim results from Phase 1/2a trial of ARO-INHBE

May 27, 2026, 7:00 AM EDT - 6 weeks ago

Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026

2026-05-26T16:29:12.000Z - 6 weeks ago

Arrowhead presents clinical cardiometabolic data at EAS Congress

May 26, 2026, 10:00 AM EDT - 6 weeks ago

Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress

May 20, 2026, 9:00 AM EDT - 7 weeks ago

Arrowhead Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 13, 2026, 10:00 AM EDT - 2 months ago

Arrowhead Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 7:00 AM EDT - 2 months ago

Arrowhead Pharmaceuticals Slides: Corporate presentation

2026-05-13T10:38:55.000Z - 2 months ago

Arrowhead price target raised to $46 from $35 at Bernstein

2026-05-08T08:35:40.000Z - 2 months ago

Arrowhead price target raised to $90 from $80 at Chardan

2026-05-07T21:01:13.000Z - 2 months ago

Arrowhead reports Q2 EPS (93c), consensus ($1.11)

May 7, 2026, 4:30 PM EDT - 2 months ago

Arrowhead Pharmaceuticals Earnings Call Transcript: Q2 2026

May 7, 2026, 4:30 PM EDT - 2 months ago

Arrowhead Pharmaceuticals Earnings release: Q2 2026

May 7, 2026, 4:30 PM EDT - 2 months ago

Arrowhead Pharmaceuticals Quarterly report: Q2 2026

May 7, 2026, 4:01 PM EDT - 2 months ago

Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results

2026-05-05T12:17:38.000Z - 2 months ago

Arrowhead announces exclusive worldwide license agreement with Madrigal Pharma

MDGL

May 5, 2026, 8:00 AM EDT - 2 months ago

Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals

MDGL

May 4, 2026, 7:30 AM EDT - 2 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events

2026-05-01T11:47:46.000Z - 2 months ago

Arrowhead announces Australian TGA approved Redemplo for FCS

May 1, 2026, 7:30 AM EDT - 2 months ago

Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)

2026-05-01T08:45:41.000Z - 2 months ago

Arrowhead initiated with an Overweight at JPMorgan

2026-04-24T10:46:32.000Z - 2 months ago

Arrowhead announces EMA recommended approval of Redemplo

Apr 24, 2026, 6:39 AM EDT - 2 months ago

Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe

Apr 21, 2026, 10:04 AM EDT - 2 months ago

This Pharma Stock Is Up 460% Over the Past Year. What Could Be Key to Future Gains.

2026-04-21T09:10:37.000Z - 2 months ago

Arrowhead upgraded to Overweight from Equal Weight at Morgan Stanley

Apr 20, 2026, 4:01 PM EDT - 2 months ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results

2026-04-20T15:29:23.000Z - 2 months ago

Arrowhead price target raised to $93 from $81 at BofA

2026-03-29T16:00:33.000Z - 3 months ago

Arrowhead presents long-term efficacy, safety data for plozasiran

Mar 28, 2026, 10:30 AM EDT - 3 months ago

Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology's 75th Annual Scientific Session and Expo

2026-03-26T15:20:29.000Z - 3 months ago

Arrowhead price target lowered to $81 from $84 at BofA

IONS

Mar 9, 2026, 2:20 PM EDT - 4 months ago

Arrowhead Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Mar 2, 2026, 11:50 AM EST - 4 months ago

Arrowhead Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 7:30 AM EST - 4 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events

2026-02-06T15:40:15.000Z - 5 months ago

Arrowhead price target lowered to $78 from $81 at Morgan Stanley

Feb 5, 2026, 4:30 PM EST - 5 months ago

Arrowhead Pharmaceuticals Earnings Call Transcript: Q1 2026

Feb 5, 2026, 4:30 PM EST - 5 months ago

Arrowhead Pharmaceuticals Quarterly report: Q1 2026

Feb 5, 2026, 4:30 PM EST - 5 months ago

Arrowhead Pharmaceuticals Earnings release: Q1 2026

Feb 5, 2026, 4:05 PM EST - 5 months ago

Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results

Feb 4, 2026, 6:15 PM EST - 5 months ago

Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600

ADT CIEN DAY DVAX OSW

2026-02-04T22:26:13.000Z - 5 months ago

Arrowhead to replace Ciena in S&P 400 at open on 2/9

CIEN

2026-02-04T22:25:49.000Z - 5 months ago

ADT Inc. to replace Arrowhead in S&P 600 at open on 2/9

ADT

2026-01-27T12:45:29.000Z - 5 months ago

Arrowhead doses first patient in ARO-DIMER-PA trial

Jan 27, 2026, 7:30 AM EST - 5 months ago

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Jan 27, 2026, 7:00 AM EST - 5 months ago

Arrowhead Pharmaceuticals Proxy statement: Proxy Filing

Jan 27, 2026, 7:00 AM EST - 5 months ago

Arrowhead Pharmaceuticals Proxy statement: Proxy Filing

Jan 20, 2026, 4:30 PM EST - 6 months ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results

Jan 12, 2026, 10:30 AM EST - 6 months ago

Arrowhead Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 11:05 PM EST - 6 months ago

Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants

Jan 7, 2026, 7:30 AM EST - 6 months ago

Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China

Jan 6, 2026, 6:14 PM EST - 6 months ago

Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock

Jan 6, 2026, 11:30 AM EST - 6 months ago

Arrowhead Pharmaceuticals Transcript: Study Update

Jan 6, 2026, 11:30 AM EST - 6 months ago

Arrowhead Pharmaceuticals Press release: Study Update

Jan 6, 2026, 11:30 AM EST - 6 months ago

Arrowhead Pharmaceuticals Slides: Study Update

Jan 6, 2026, 11:26 AM EST - 6 months ago

Zepbound Boost Gets a Lift From Arrowhead's Drug. The Question Is Whether Patients Will Pay.

Jan 6, 2026, 7:30 AM EST - 6 months ago

Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition

Jan 5, 2026, 7:30 AM EST - 6 months ago

Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Dec 23, 2025, 7:30 AM EST - 7 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events

Dec 15, 2025, 4:30 PM EST - 7 months ago

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Dec 8, 2025, 7:30 AM EST - 7 months ago

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

Dec 8, 2025, 7:00 AM EST - 7 months ago

Arrowhead Pharmaceuticals Slides: Corporate presentation

Dec 4, 2025, 10:00 AM EST - 7 months ago

Arrowhead Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 10:30 AM EST - 7 months ago

Arrowhead Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 7:30 AM EST - 7 months ago

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia

Dec 1, 2025, 4:00 PM EST - 7 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences

Nov 25, 2025, 4:30 PM EST - 8 months ago

Arrowhead Pharmaceuticals Earnings Call Transcript: Q4 2025

Nov 25, 2025, 4:30 PM EST - 8 months ago

Arrowhead Pharmaceuticals Annual report: Q4 2025

Nov 25, 2025, 4:30 PM EST - 8 months ago

Arrowhead Pharmaceuticals Earnings release: Q4 2025

Nov 25, 2025, 4:00 PM EST - 8 months ago

Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results

Nov 24, 2025, 1:30 PM EST - 8 months ago

Arrowhead Pharmaceuticals Transcript: TD Cowen Treatment Advancements in Obesity and Related Disorders Summit

Nov 24, 2025, 7:30 AM EST - 8 months ago

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

SRPT

Nov 19, 2025, 6:00 AM EST - 8 months ago

Arrowhead Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 1:30 PM EST - 8 months ago

Arrowhead Pharmaceuticals Transcript: Study Result

Nov 18, 2025, 1:30 PM EST - 8 months ago

Arrowhead Pharmaceuticals Press release: Study Result

Nov 18, 2025, 11:52 AM EST - 8 months ago

Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Nov 18, 2025, 11:21 AM EST - 8 months ago

US FDA approves Arrowhead's genetic disorder drug

Nov 6, 2025, 4:30 PM EST - 8 months ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results

Nov 4, 2025, 7:30 AM EST - 8 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences

Oct 21, 2025, 7:30 AM EDT - 9 months ago

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis

Oct 7, 2025, 7:30 AM EDT - 9 months ago

Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Sep 11, 2025, 7:30 AM EDT - 10 months ago

Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals

Sep 10, 2025, 11:30 AM EDT - 10 months ago

Arrowhead Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 10, 2025, 7:30 AM EDT - 10 months ago

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

Sep 9, 2025, 10:30 AM EDT - 10 months ago

Arrowhead Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 9:10 AM EDT - 11 months ago

Arrowhead Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 1:00 PM EDT - 11 months ago

Arrowhead Pharmaceuticals Transcript: Citi's Biopharma Back to School Conference

Sep 2, 2025, 8:13 AM EDT - 11 months ago

Arrowhead and Novartis agree up to $2 billion deal for license to neuromuscular therapy

NVS

Sep 2, 2025, 7:30 AM EDT - 11 months ago

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement

Aug 27, 2025, 7:30 AM EDT - 11 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences

Aug 13, 2025, 4:10 PM EDT - 11 months ago

Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Arrowhead Pharmaceuticals Earnings Call Transcript: Q3 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Arrowhead Pharmaceuticals Earnings release: Q3 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Arrowhead Pharmaceuticals Quarterly report: Q3 2025

Aug 7, 2025, 4:01 PM EDT - 1 year ago

Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results

Aug 1, 2025, 6:30 AM EDT - 1 year ago

Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi

Jul 28, 2025, 7:30 AM EDT - 1 year ago

Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics

SRPT

Jul 23, 2025, 8:00 AM EDT - 1 year ago

Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics

Jul 21, 2025, 4:01 PM EDT - 1 year ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results

Jul 8, 2025, 7:30 AM EDT - 1 year ago

Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

Jun 23, 2025, 7:30 AM EDT - 1 year ago

Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran

skeezbag Jul. 9 at 6:40 PM

$ARWR weekly visit to the babysitter to ask for permission

1 · Reply

aliliimr Jul. 9 at 9:36 AM

3 · Reply

CDMO Jul. 9 at 7:47 AM

$ARWR IONS having a hard time

0 · Reply

Quantumup Jul. 8 at 3:49 PM

0 · Reply

BillionerOfKing Jul. 7 at 10:43 PM

0 · Reply

skeezbag Jul. 7 at 7:55 PM

$ARWR now ask yourself why the fake analyst is dropping coverage He has fcs/shtg? He/him is pregnant? M+a table finally flipped?

2 · Reply

johnnygogogo Jul. 7 at 7:40 PM

$ARWR peace out brotha, your fake coverage was always the fakest. @skeezbag

0 · Reply

Jschwarma Jul. 7 at 6:37 PM

$ARWR Leerink dropping coverage, so long Mani!!

2 · Reply

magross24 Jul. 7 at 4:37 PM

$ARWR they are trying so hard!

0 · Reply

magross24 Jul. 7 at 3:40 PM

$ARWR XBI is a freight train…it’s going to be harder to suppress ARWR share price…

0 · Reply

skeezbag Jul. 7 at 1:54 PM

$ARWR Monday was not supposed to be an up day so happy fake Tuesday

1 · Reply

liamsniperalert Jul. 7 at 1:49 PM

Opened 20 $ARWR 87.5C 07/17 @ $2.60 (ActualCost: $2.60)

0 · Reply

Nosh Jul. 7 at 12:49 PM

$ARWR May enter here today. (FC)

0 · Reply

NeverFadeTheOracle Jul. 7 at 11:22 AM

$ARWR PT 100

0 · Reply

StockingStuffer2832 Jul. 6 at 11:34 PM

$ARWR im ready for triple digits so i can start selling $130+ Strike calls.

1 · Reply

Jschwarma Jul. 6 at 8:21 PM

$ARWR $VRTX with a 100% premium BO of $CRNX M&A everywhere

0 · Reply

skeezbag Jul. 6 at 6:44 PM

$ARWR need more bearish posts

1 · Reply

LeftyT Jul. 6 at 6:39 PM

$ARWR added a couple Jan $75 calls at 22.11 to my long term holding. should be in triple figures by end of Sept.

0 · Reply

Jblack500 Jul. 6 at 5:52 PM

$ARWR nice ath

0 · Reply

CDMO Jul. 6 at 4:46 PM

$ARWR so juicy

0 · Reply

STOCKROCKER8 Jul. 6 at 4:40 PM

$ARWR 👌

0 · Reply

Fast_Branch Jul. 6 at 3:33 PM

$ARWR Nice breakout on daily chart, beautiful push on intraday chart.

0 · Reply

Market Cap	12.08B
Revenue (ttm)	829.45M
Net Income (ttm)	-1.63M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-0.20%
Debt to Equity Ratio	1.47

Volume	1,437,700
Avg Vol	2,072,058
Day's Range	N/A - N/A
Shares Out	140.86M
Stochastic %K	63%
Beta	1.26
Analysts	Strong Sell
Price Target	$88.77